The EU’s JURI committee has backed removing the six-month stockpiling limit for biosimilars under the SPC waiver, a move welcomed by Medicines for Europe as a boost to EU manufacturing, competition and day-one market entry.
The EU’s JURI committee has backed removing the six-month stockpiling limit for biosimilars under the SPC waiver, a move welcomed by Medicines for Europe as a boost to EU manufacturing, competition and day-one market entry.